Company Overview
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 14.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $6.65M (-51.2% YoY); net profit $-136.31M.
- Trailing 12 Months Year-on-year growth — revenue +9.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 14.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 14.30% |
| 1 Year: | 9.20% |
Stock Price Performance
| 1 Year: | +86.73% |
| 6 Months: | +58.65% |
| 3 Months: | -13.17% |
| 1 Month: | -9.44% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)46.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 14.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 32.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FATE Fate Therapeutics, Inc. R2KPHARMA | 2.11 | -2.01 | $252.82M | 0.00% | -52.22% | -60.75% | 14.30% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.03M | 1.66M | 2.63M | 2.82M | 2.43M | 2.80M | 2.52M | 5.46M | 7.56M | 11.14M | 13.41M | 14.22M | 18.41M | 18.55M | 14.98M | 58.98M | 933.00K | 1.94M | 1.93M | 6.77M | 3.07M | 1.63M | 1.91M | 1.74M | 1.30M |
| Operating Income | - | -7.32M | -7.22M | -6.33M | - | -7.92M | -8.00M | -8.39M | - | -9.97M | -9.57M | -10.34M | - | -14.05M | -19.61M | -16.69M | - | -20.45M | -24.08M | -27.12M | - | -34.49M | -28.71M | -31.49M | -46.21M | -46.78M | -54.62M | -74.47M | -83.11M | -86.39M | -28.59M | -62.56M | -51.28M | -51.07M | -45.08M | -52.38M | -41.28M | -36.97M | -34.73M | -33.00M |
| Net Income | -6.23M | -7.88M | -7.78M | -6.89M | -7.45M | -8.38M | -8.41M | -8.74M | -7.94M | -10.13M | -9.64M | -10.68M | -12.50M | -14.13M | -19.65M | -16.78M | -16.03M | -19.76M | -23.48M | -26.61M | -28.30M | -33.52M | -28.07M | -58.68M | -45.09M | -55.13M | -43.31M | -65.69M | -76.11M | -83.56M | -18.88M | -52.76M | -45.17M | -48.00M | -38.43M | -47.68M | -37.62M | -34.07M | -32.25M | -31.21M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.58 | -0.45 | -0.68 | -0.79 | -0.86 | -0.19 | -0.54 | -0.46 | -0.47 | -0.33 | -0.40 | -0.32 | -0.29 | -0.27 | -0.26 |
| R&D Expense | - | 4.57M | 4.86M | 5.00M | - | 6.64M | 6.78M | 6.80M | - | 7.97M | 7.93M | 8.58M | - | 11.48M | 16.82M | 13.64M | - | 17.73M | 21.63M | 23.20M | - | 29.28M | 26.67M | 30.69M | 44.85M | 48.02M | 53.13M | 72.14M | 81.31M | 79.82M | 65.63M | 40.88M | 34.27M | 32.14M | 34.60M | 34.65M | 29.14M | 27.43M | 25.84M | 24.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1.17M | 2.67M | 971.00K | - | 2.43M | 4.40M | 4.11M | 4.74M | 10.68M | 31.43M | 55.85M | 96.30M | 63.53M | 13.63M | 6.65M |
| Operating Income | - | - | - | -13.29M | -13.56M | -17.68M | -24.90M | -27.78M | -31.96M | -42.12M | -67.09M | -100.73M | -128.09M | -216.99M | -308.39M | -190.51M | -210.28M | -147.70M |
| Net Income | -7.17M | -13.33M | -16.22M | -13.43M | -14.24M | -20.89M | -25.88M | -29.99M | -33.46M | -42.95M | -66.60M | -98.15M | -173.39M | -212.15M | -281.72M | -160.93M | -186.26M | -136.31M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -2.10 | -2.24 | -2.91 | -1.64 | -1.64 | -1.15 |
| R&D Expense | - | - | - | 9.86M | 12.00M | 12.01M | 16.43M | 19.86M | 26.45M | 34.36M | 56.02M | 87.77M | 125.62M | 215.52M | 320.45M | 172.60M | 135.00M | 107.83M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | 11.08M | 55.58M | 51.18M | 67.96M | 95.05M | 105.29M | 213.03M | 302.27M | 622.46M | 921.46M | 705.56M | 506.22M | 440.69M | 318.94M |
| Total Equity | -1.22M | -8.35M | -21.46M | -37.44M | -50.68M | -52.83M | 50.85M | 28.34M | 38.04M | 73.15M | 77.19M | 160.47M | 244.76M | 384.44M | 678.84M | 483.94M | 368.42M | 318.73M | 207.18M |
| Cash & Equivalents | - | - | - | 11.22M | 6.39M | 9.09M | 54.04M | 49.10M | 64.81M | 88.61M | 88.95M | 190.51M | 99.81M | 167.35M | 133.58M | 61.33M | 41.87M | 36.06M | 46.63M |
| Long Term Debt | - | - | - | - | - | 1.73M | 1.75M | 18.07M | 10.69M | 2.50M | 14.81M | 12.45M | - | - | - | - | - | - | - |
| Current Liabilities | - | - | - | - | - | 4.85M | 4.60M | 4.57M | 13.44M | 15.19M | 11.05M | 27.26M | 27.81M | 85.56M | 81.28M | 114.05M | 39.09M | 38.52M | 36.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -29.82M | -36.82M | -38.65M | -83.17M | -39.23M | -162.87M | -248.21M | -132.26M | -122.87M | -106.08M |
| Investing Cash Flow | - | - | - | - | - | -4.11M | -10.20M | -463.00K | -157.45M | -161.08M | -324.02M | 166.75M | 112.67M | 12.22M | 111.17M |
| Financing Cash Flow | - | - | - | - | - | 57.74M | 47.36M | 140.78M | 149.93M | 282.84M | 453.13M | 9.21M | 85.00K | 99.89M | 5.49M |
| Capital Expenditure | -2.00K | -709.00K | -244.00K | -882.00K | -1.50M | -457.00K | -1.73M | -2.30M | -7.39M | -4.93M | -50.70M | -35.57M | -6.15M | -730.00K | -5.95M |
| Free Cash Flow | - | - | - | - | - | -30.28M | -38.54M | -40.95M | -90.57M | -44.16M | -213.57M | -283.77M | -138.42M | -123.60M | -112.04M |
| Share Buybacks | 7.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -1,136.2% | -507.8% | -1,820.3% | - | -1,142.8% | -726.1% | -1,025.9% | -1,415.4% | -943.1% | -407.5% | -388.6% | -320.2% | -299.9% | -1,542.6% | -2,222.4% |
| Net Margin % | - | - | - | -1,147.6% | -533.3% | -2,151.8% | - | -1,233.7% | -760.2% | -1,046.1% | -1,405.0% | -919.0% | -551.6% | -379.9% | -292.5% | -253.3% | -1,366.5% | -2,051.1% |
| ROE % | 85.8% | 62.1% | 43.3% | 26.5% | 27.0% | -41.1% | -91.3% | -78.8% | -45.7% | -55.6% | -41.5% | -40.1% | -45.1% | -31.3% | -58.2% | -43.7% | -58.4% | -65.8% |
| ROCE % | - | - | - | - | -217.7% | -34.7% | -53.4% | -51.0% | -40.0% | -44.7% | -36.1% | -36.7% | -23.9% | -25.8% | -52.1% | -40.8% | -52.3% | -52.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Redmile Group, LLC | 10.74% | 12.87M | $28.06M |
| 2 | Blackrock Inc. | 6.09% | 7.30M | $15.91M |
| 3 | Vanguard Portfolio Management LLC | 3.79% | 4.55M | $9.91M |
| 4 | Vanguard Capital Management LLC | 3.71% | 4.45M | $9.69M |
| 5 | Acadian Asset Management. LLC | 3.63% | 4.35M | $9.49M |
| 6 | AQR Capital Management, LLC | 3.20% | 3.84M | $8.37M |
| 7 | Two Sigma Investments, LP | 3.00% | 3.59M | $7.83M |
| 8 | Johnson & Johnson | 2.82% | 3.38M | $7.37M |
| 9 | Renaissance Technologies, LLC | 2.49% | 2.98M | $6.50M |
| 10 | Millennium Management Llc | 2.03% | 2.43M | $5.31M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FATE
Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside - TradingView
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNdHZhWVZ1ZGhad3pfSU16ek81TENvMEhCZ3ROVDhnR0Iyd0JGQVJsd3NDUnB6X01DeFlhY202UF9KeG50d190NklIMzdWS3A3UG1NTzBGd3k1b3lJZWVGbl9ub0NhQnZnV1pXM0lxZF9aX0diRFNfVGZvdnA4dEtHUm9fSVhhYVJPWExEeU…
1,165,927 Fate Therapeutics, Inc. $FATE Shares Bought by Assenagon Asset Management S.A. - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNeGN6VG90ZThHYl9NbmVhTllOdlhBTEVPVmg5VW5RMjk1LUtkWDBGVDE1bGJ3OElFdVZYNEJJLWQyY00tbHZKSlpfRVpTWjc0WGVYX0huQWpuN0tfaUx6ZnBrX29JZEVZaExWdXlyY3lCYlg1Um9USUFmZTFacXF6TmJaNGFvVHdjY04tMV…
Bloomberg Analyst Doubles Down on $10,000 Bitcoin Call, Tying Fate to a 20% Stock Slump - BigGo Finance
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFBRQkIwQ2g0ZVFmdzZLVjc0MHYxQ0s1ejBqRXRUdzgwaVVDYXRmR2pMUkN6MU1oWHgzZ3hnYV9CakFOc2JvcWMtbnpxVklNMWZka0E3TG5YYXpfalNBMGVfQXBpLWNEeFo1elE3MTN1SEU0ZWZlM1E?oc=5" target="_blank">Bloomber…
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPckV6Q192ZXZKMjdXU1o1TXJPQmRDVTBHV0hzVFVZOXRRSVVaOGdfUW1ualdmTUxsTHBsbUs0dzA1QmxCNm1JSzhTaXpRZGFzdTJxeHRJUUgyNjNEb2tqSVVTMlVOdnpKNW5XeFNleVFrc2VMd0JQSDZYcVNqLXJrS0c5S0FqbC1iMVBFdG…
Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPalowaWppNUtGWEZLbjg5YzBuUUJwWlVBWVJQSFM2QzVzR0NQV25CUHVtdkpTWVByNHEwc3N4VWtsNUhoRjNJT2YxOEpFc3VJOS1jZVNRd3VjQ0JsLUZ1akIwS2VqM3JneTIxNm40YWJLZFVWdldfUWJTclNDRlhUY1BWdDhCZm9Ed3Z1N0…
Can Genomics Alter Fate of Diagnostic Stock at 10-Year Low P/E? - Equitymaster
<a href="https://news.google.com/rss/articles/CBMizwJBVV95cUxNTjl1dUdDREFkMzlyTnNLMmd2VzhNS0Z5RnJVVmwtc3hEbmFXMmhVaEluWEZNSFNzaWFEdDhLM3BqT21oTGM4bUJDTUFPNnJ4OVZiTl9BcWVGLVlmMmZ3ZGdjMF9qU2NEOU1ROWdST05tN05WbnQzODIxQXJfMHdCSmJnM2U4S21XeWFoU3…
FATE — Frequently Asked Questions
What is the current share price of Fate Therapeutics, Inc. (FATE)?
As of 2026-10-23 16:27 PDT, Fate Therapeutics, Inc. (FATE) trades at $2.11 on NasdaqGM. Its 52-week range is $0.95 to $3.11.
What is the market capitalisation of FATE?
Fate Therapeutics, Inc. (FATE) has a market capitalisation of $252.82M on NasdaqGM.
What is the P/E ratio of FATE?
FATE trades at a trailing price-to-earnings (P/E) ratio of -2.01. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.66.
What is the return on equity (ROE) of FATE?
FATE has a return on equity (ROE) of -60.75%. Its return on capital employed (ROCE) is -52.22%.
Is FATE a good stock to buy?
This page provides a data-driven analysis of Fate Therapeutics, Inc. (FATE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.